Cara Therapeutics, VFMCRP get EC approval for Kapruvia for pruritus

pallavi123- May 1, 2022

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) said that Kapruvia (difelikefalin) has secured approval from the European Commission (EC) for the treatment ... Read More

Chinook Therapeutics gets orphan drug status from EC for atrasentan in IgAN

pallavi123- December 15, 2021

Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy ... Read More

EC approves sale of Aegon’s CEE businesses to Vienna Insurance

Pallavi Madhiraju- August 13, 2021

The European Commission (EC) has approved the €830 million sale of Dutch insurance group Aegon’s Central and Eastern European (CEE) businesses to Vienna Insurance Group ... Read More

Aon, Willis Towers Watson $30bn merger gets EC approval

Pallavi Madhiraju- July 11, 2021

Aon and Willis Towers Watson said that the European Commission (EC) has given conditional approval for their proposed $30 billion merger deal. The all-stock deal ... Read More

Aon to sell German retirement and investment business to Lane Clark & Peacock

Pallavi Madhiraju- May 17, 2021

Professional services firm Aon has agreed to divest its German retirement and investment business to Lane Clark & Peacock (LCP) for an undisclosed price. The ... Read More

Bioniz Therapeutics gets EC orphan drug status for BNZ-1 for CTCL

pallavi123- April 6, 2021

Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type ... Read More

Janssen Covid‑19 vaccine gets conditional marketing authorization in EU

pallavi123- March 27, 2021

The European Commission has granted a conditional marketing authorization (CMA) for the single dose Janssen Covid‑19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson ... Read More

BMS gets Opdivo EC approval for second-line treatment of ESCC

pharmanewsdaily- November 24, 2020

Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More

BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC

pharmanewsdaily- November 8, 2020

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More

EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate

pharmanewsdaily- October 9, 2020

Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 ... Read More